EcoDrugPlus

Dna Topoisomerase 2-Beta-Like

Ensembl ID : ENSSTUG00000047167
Gene Symbol: LOC115175684
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSSTUG00000039834
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSTUG00000004672
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna-(Apurinic Or Apyrimidinic Site) Lyase-Like

Ensembl ID : ENSSTUG00000003069
Gene Symbol: LOC115199169
3 Cross references
205 Possible Orthologues:

Dna-(Apurinic Or Apyrimidinic Site) Lyase-Like

Ensembl ID : ENSSTUG00000044403
Gene Symbol: LOC115180410
3 Cross references
208 Possible Orthologues:

E3 Ubiquitin-Protein Ligase Mdm2-Like

Ensembl ID : ENSSTUG00000022615
Gene Symbol: LOC115182930
3 Cross references
281 Possible Orthologues:

E3 Ubiquitin-Protein Ligase Mdm2-Like

Ensembl ID : ENSSTUG00000026638
Gene Symbol: LOC115182075
3 Cross references
281 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSSTUG00000012648
Gene Symbol: EML4
3 Cross references
201 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSSTUG00000038658
Gene Symbol: EPHA3
3 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSSTUG00000013099
Gene Symbol: EPHA3
3 Cross references
206 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSSTUG00000026525
Gene Symbol: F2RL3
3 Cross references
189 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSSTUG00000034679
Gene Symbol: F2RL3
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).